Emerging Treatment Modalities in Metastatic Breast Cancer: Highlights from SABCS 2022 and Beyond : Episode 3
Use of Second-Generation Oral SERDs in ER+/HER2- mBC
Dr Komal Jhaveri highlights important data on oral SERDs for ER-positive HER2-negative mBC that was presented at recent meetings.
EP: 1.Overview of ER+/HER2- Metastatic Breast Cancer (mBC)
EP: 2.Standards of Care in the Frontline Treatment of ER+/HER2- mBC
Now Viewing
EP: 3.Use of Second-Generation Oral SERDs in ER+/HER2- mBC
EP: 4.The Role of Capivasertib in ER+/HER- mBC
EP: 5.Standard Practices for the Management of Triple-Negative Breast Cancer (TNBC)
EP: 6.The Role of ADCs in the Treatment of TNBC
EP: 7.Investigational ADCs for Treatment of TNBC
EP: 8.Emerging Concepts in mBC Treatment
Related Videos
Related Content
